Publications by authors named "Daniela Cardemil"
Background: Philadelphia-negative myeloproliferative neoplasms (Ph-MPN) are chronic hematological disorders characterized by the overproduction of one or more mature myeloid blood cell lineages. Classical Ph-MPN are polycythemia vera (PV), essential thrombocytopenia (ET) and primary myelofibrosis (PMF).
Aim: To assess the epidemiological, clinical and diagnostic characteristics of Ph-MPN in Chile.
Article Synopsis
- Philadelphia-negative myeloproliferative neoplasms (Ph-MPN) are chronic blood disorders marked by excessive production of myeloid blood cells, with major types being polycythemia vera (PV), essential thrombocytopenia (ET), and primary myelofibrosis (PMF).
- A study in Chile reviewed the medical records of 462 patients referred for MPN from 2012 to 2017, finding that ET was the most common type, with a reported incidence of 1.5 cases per 100,000 people.
- Despite extensive testing for the JAK2 V617F mutation, only 30% of patients underwent a bone marrow biopsy, and overall survival was 87
Article Synopsis
- The study examined the clinical and survival characteristics of transplant-eligible multiple myeloma patients in Latin America, focusing on the differences between public and private healthcare systems.
- It included data from 1293 patients diagnosed from 2010 to 2018, highlighting significant disparities in outcomes and survival rates between those treated in public versus private institutions.
- The findings suggest that late diagnosis and limited access to effective treatments in public facilities contribute to poorer survival rates, while patients receiving modern therapies and autologous stem cell transplants have survival rates comparable to international standards.
Background The treatment of choice of newly diagnosed multiple myeloma (NDMM) is an induction with proteasome inhibitors followed autologous stem cell transplantation (HSCT). Since 2013, the treatment of these patients in the public system is based on CTD (cyclophosphamide, thalidomide, and dexamethasone). Aim To evaluate the response rates achieved with CTD, and the results of HSCT in patients with NDMM in the public setting.
View Article and Find Full Text PDFArticle Synopsis
- - Waldenström macroglobulinemia (WM) is a rare and slow-growing type of B-cell lymphoma characterized by the growth of lymphoplasmacytic cells and the production of a specific protein called IgM.
- - A study analyzed the medical records of 31 WM patients in a Chilean hospital from 2002 to 2017, finding that most had bone marrow involvement and varying risk levels according to the International Prognostic Score System for WM.
- - Among those treated, 81% received therapies like plasmapheresis and rituximab, with a 5-year overall survival rate of 74%, suggesting that while survival rates are generally in line with global statistics, improvements may arise with better treatment approaches.*
Background: Multiple myeloma (MM) is one of the most common malignancies found in hematology.
Aim: To describe the features of patients with MM and perform a survival analysis according to the different treatment protocols used between 2000 and 2016.
Material And Methods: Analysis of the database of the Chilean national anti-neoplastic drug program.
Intrathecal chemotherapy may be complicated with the development of myelopathies or toxic radiculopathies. This myeloradicular involvement, of toxic character, is unpredictable, since these patients have repeatedly received Intrathecal chemotherapy with the same drugs without apparent injury. The toxic effect should be mainly attributed to Cytarabine and not to methotrexate, since the central nervous system lacks Cytidine deaminase, the enzyme that degrades Cytarabine.
View Article and Find Full Text PDFBackground: The first line treatment for patients < 40 years old with aplastic anemia (AA) is allogeneic HLA-identical sibling donor transplantation (SCT). Immunosuppressive therapy (IST) with a combination of Thymoglobuline (ATG) and cyclosporine is used for older patients or those without a donor. Five year overall survival (OS) for both therapies is > 70%.
View Article and Find Full Text PDFArticle Synopsis
- * The case highlights a young female whose AA worsened while she was pregnant, presenting extremely low levels of hemoglobin, leukocytes, and platelets.
- * Despite initial treatments with cyclosporine and thymocyte globulin, her condition did not improve, and she ultimately required a cesarean section and ongoing transfusions postpartum.